Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole by M. Chappe et al.
Journal de Mycologie Me´dicale xxx (2018) xxx–xxx
G Model
MYCMED-790; No. of Pages 3Case report/Cas clinique
Successful treatment of a recurrent Aspergillus niger otomycosis with
local application of voriconazole
M. Chappe a, S. Vrignaud a,*, L. de Gentile b, G. Legrand c, F. Lagarce a,d, Y. Le Govic b,e
a Pharmacie Centrale, CHU d’Angers, 49933 Angers, France
b Laboratoire de parasitologie-mycologie, CHU d’Angers, 49933 Angers, France
cCabinet d’otorhinolaryngologie, clinique de l’Anjou, 49000 Angers, France
d Inserm U1066, CNRS 6021, micro- et nanome´decines biomime´tiques, universite´ Bretagne-Loire, 49933 Angers, France
eGroupe d’e´tude des interactions Hoˆte–Pathoge`ne, EA 3142, universite´ Bretagne-Loire, 499333 Angers, France
A R T I C L E I N F O
Historique de l’article :
Received 19 December 2017
Received in revised form 21 March 2018
Accepted 22 March 2018
Keywords:
Aspergillus niger
Otomycosis
Otitis externa
Voriconazole
Nystatin
A B S T R A C T
Fungal otitis (otomycosis) is a common infection encountered by otolaryngologists. Nevertheless, its
management can be challenging because of its high recurrence rate and of the limited therapeutic
options. A 45-year-old woman suffered from recurrent otomycosis. The ineffectiveness of successive
antibiotic cures and repeated topical treatments with nystatin and then with econazole cream led to
perform microbiological analyses. Culture of ear swab grew Aspergillus niger. The use of a 1% voriconazole
sterile solution previously validated for treatment of eye infections was considered after ensuring the
absence of known ototoxic effects of the antifungal and of the excipients. The patient was advised to
apply locally this voriconazole solution daily for 14 days (3 drops, 3–4 times a day). Full recovery was
obtained at the end of the treatment, and no relevant side effects were noticed. More than one year after
completion of therapy, there was no recurrence. Our observation shows that voriconazole 1% solution is
an interesting option for treating otomycosis which failed to respond to usual therapeutic options.
Further prospective studies are now warranted to confirm these findings.
C 2018 Elsevier Masson SAS. All rights reserved.
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Otomycosis is a fungal infection of the outer ear canal (OEC). It
accounts for approximately 10% of all acute otitis externa cases
[1]. Anatomical characteristics of the OEC indeed provide ideal
conditions for such infections, which mainly involve species
belonging to the Aspergillus (especially A. niger and A. fumigatus) or
Candida genus [2]. Risk factors for such infections include warm,
moist weather, and excessive accumulation of cerumen in the OEC.
This is particularly true when the OEC remains wet after swimming
or bathing. Although usually benign, management of otomycosis
may be challenging because of its high recurrence rate [1], the
paucity of therapeutic options and the emergence of antifungal
resistance [3,4]. Besides patient’s discomfort, its possibility to
evolve towards an invasive fungal infection justifies appropriate
care. Here, we report the first case of recurrent A. niger otomycosis
that was successfully treated by topical administration of a 1%
voriconazole solution along with a literature review of antifungal
therapy of A. niger otomycosis.* Corresponding author.
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In March 2015, a 45-year-old woman practicing swimming
consulted her family doctor complaining of left auricular pain,
hearing loss, and tinnitus, along with changes in her tone of voice.
Eardrum was undamaged. The patient was given ofloxacin
eardrops, 1.5 mg bid for 7 days, followed by a 5-day course of
cefpodoxime per os 100 mg bid. Despite compliance to treatment,
the symptoms did not improve and black residues appeared in the
OEC. Fifteen days later, during an otorhinolaryngology consulta-
tion, an ear cleaning suction was performed and a local treatment
with nystatin (Auricularum1, Grimberg) was prescribed for
15 days; eardrops were instilled twice daily. There was a marked
improvement but clinical signs reappeared quickly. Microbiolog-
ical examination was undertaken and mycological cultures from a
swab taken from the OEC grew Aspergillus niger, which was
identified morphologically according to standard descriptions
[5]. The same local treatment was prescribed for a further 15 days,
along with custom-made earplugs to prevent water penetration
into the ear canal during aquatic activities.
In July 2015, during a consultation in mycology, and following
another 15-day course of local nystatin, a yellowish material was
sampled from the left OEC, but cultures remained sterile. Despite
clinical recurrence and significant discomfort, the possibility oft of a recurrent Aspergillus niger otomycosis with local application
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was rejected given the potential side effects associated with
systemic delivery and the lack of consensus on its implementation
in this indication. The patient no longer used the earplugs and
stopped going to the swimming pool.
Seven months later, i.e., about one year post-onset of
symptoms, the patient came back to our hospital. A total of
4 clinical recurrences were noticed, and the symptoms worsened
with the appearance of eczema-like lesions at the level of the
tragus and antitragus, discharge flowing down the left earlobe, and
severe itching. Blackish debris were removed from the left ear,
allowing the recovery of A. niger again by cultures (Fig. 1A and 1B).
In this context, an antifungal susceptibility testing was performed
on the patient’s isolate using nystatin and voriconazole by the disk
diffusion and E-test methods, respectively (Fig. 1C). A very slight
inhibition zone (11 mm) was noticed around the nystatin disk,
indicating little activity against this strain, which probably
contributed to disease relapses. By contrast, voriconazole exhibi-
ted excellent in vitro activity, with a minimal inhibitory
concentration of 0.064 mg/mL, which is markedly lower than the
epidemiological cutoff value reported for voriconazole against
A. niger [6]. Meanwhile, a treatment with econazole cream was
started but such formulation was difficult to apply due to the deep,
peritympanic spread of the fungus. The hospital pharmacy was
contacted to investigate the possibility of using an azole-based
aqueous solution as eardrops. Finally, a 1% voriconazole ophthal-
mic solution was chosen, used outside of marketing authorisation,
after excluding ototoxicity risks due to the eye drop components.Fig. 1. Mycological investigations performed on ear wax mass. A. Macroscopic
aspect of culture on Sabouraud’s agar, consistent with Aspergillus niger. B.
Observation of an A. niger colony with a binocular magnifier, showing hyaline
conidiophores bearing dark-brown conidial heads. C. Susceptibility testing of
A. niger against nystatin (disk diffusion) and voriconazole (E-test).
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3 to 4 times a day for 14 days.
Complete recovery was achieved at the end of treatment with
voriconazole without any side effects. The skin of the OEC became
normal and the patient was advised to avoid swimming for some
time and reuse of the silicone earplugs to prevent further fungal
colonization. At the two-month follow-up visit, otoscopic exami-
nation was unremarkable and ear swab cultures remained sterile,
indicating mycological cure. More than one year after completing
treatment, the patient had no recurrence of otitis.
3. Discussion
In France, nystatin is the only antifungal licensed as a powder or
as suspension (in combination with oxytetracycline, polymyxin B
and dexamethasone) for local treatment of otomycosis [7]. Since
other antifungals are not available in a formulation suitable for
auricular use, the prescription of nystatin is recommended as the
first-line treatment of otomycosis for up to 15 days. Like
amphotericin B, nystatin exhibits a broad spectrum including
the aspergilli and Candida yeasts, which are mostly responsible for
otomycosis. However, lack of efficacy has been reported in several
cases of Aspergillus otomycoses [8,9]. Several other ototopical
antifungals are available in some countries, but the most effective
drug in this context remains to be defined. Clotrimazole is the most
widely used topical imidazole [9]. In the USA, it is considered as the
drug of choice for treatment of uncomplicated otomycosis [10]. It
displays a high in vitro activity against most yeasts and molds [11]
and success rates ranging from 50% to 100% have been reported
[12–14]. However, all these studies were conducted on a limited
number of patients, and effectiveness was often based on symptom
resolution rather than mycological assessments.
Consequently, whether or not treatment failures with clotri-
mazole could be attributed to a particular pathogen, i.e., A. niger, is
unknown. Miconazole and bifonazole, as well as ciclopiroxola-
mine, can also be used. Compared to clotrimazole, the two
imidazole drugs exhibit similar activity, but varying from one
fungal species to another. For instance, del Palacio et al. [15]
investigated the efficacy of topical bifonazole on 40 infected ears
and they found a clinical cure for 72.5% of them while mycological
cure rate reached 57.5%. Of note, during long-term follow-up (2–5
years), 10 ears were re-infected, 8 of them with A. niger at baseline.
These results are in line with another study also performed by del
Palacio et al. [16]. Among the 40 infected ears treated with a
ciclopiroxolamine-based preparation, seven (17.5%) relapses were
noticed, of which four (10%) were due to A. niger [16]. The
effectiveness of ciclopiroxolamine versus miconazole was also
investigated [17]. Ciclopiroxolamine showed a narrower spectrum,
since it inhibited only 57% of the selected strains compared to 90%
with miconazole [17]. Terbinafine also showed a potent in vitro
antifungal activity against several aspergilli, including A. niger
[18,19]. Unfortunately, ototoxic effects of topically administered
terbinafine have been reported in an animal model [20], thus
limiting its usefulness in the field. Unlike terbinafine, tolnaphtate
was not ototoxic in animal models [12], but it is ineffective against
A. niger [11].
In our case, relapse could be attributed to an insufficient activity
of nystatin against the causative agent, as attested by our
experimental data. Multiple recurrences of otomycosis could also
be explained by the use of oral and topical antibiotics, which may
have destabilized the local flora and permitted fungal proliferation,
or by the use of earplugs during aquatic activities, a possible source
of re-infection [12].
To treat these recalcitrant forms, prescribers must seek an
alternative among the antifungal medications classically used byt of a recurrent Aspergillus niger otomycosis with local application
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beyond marketing authorization. Such a procedure requires the
patient’s consent as well as the verification of the tympanic
membrane integrity. In the present case, nystatin treatment was
switched to econazole cream, but its effect was limited due to poor
penetration of this formulation into the OEC. Econazole is also
available as a solution but it is applied using a pressurized vial,
which is not suitable for direct application into the OEC.
Another therapeutic option compatible with auricular applica-
tion and effective on the isolated fungus was therefore searched.
According to the European Pharmacopoeia, auricular solution
intended for application to an injured ear should be sterile and
free of antimicrobial preservatives and should not induce toxic
effects or local irritation [21]. Given the urgency of the situation
and the results of antifungal susceptibility testing, it was decided
to investigate the opportunity of using a sterile voriconazole
solution prepared by the AP–HP (Assistance publique-Hoˆpitaux de
Paris, Paris, France) in the form of eye drops in multi-dose vials
(8 mL), and containing voriconazole 10 mg/mL and beta-cyclodex-
trin sulfobutyl ether sodium salt 160 mg/mL as stabilizing agent.
Although the effectiveness of oral voriconazole for the treatment of
Aspergillus otitis has been reported [22], a twelve-week duration
therapy was required, with the risk of side effects. Conversely, the
topical use of voriconazole solution for treatment of otomycosis
has never been reported to date. The pharmacists’ approach was to
check the absence of ototoxicity. A bibliographical search did not
reveal ototoxic effects regarding the local administration of the eye
drop solution components, voriconazole and cyclodextrin, which
was confirmed by making inquiries to Pfizer laboratory (which
markets voriconazole products) and contacting the Regional
Pharmacovigilance Centre. Furthermore, the physicochemical
properties of this formulation were considered to be safe and
compatible with ear instillation (pH: 7.0  0.1, osmolarity:
562  10 mosm/L) [23]. Finally, this treatment was prescribed, which
allowed to cure the patient. To our knowledge, this is the first report
on the safety and efficacy of a 1% sterile voriconazole solution to treat
a recurrent, nystatin-resistant otomycosis. The local application of
this molecule avoids systemic treatment for an extended period,
potentially responsible for undesirable effects. These data should be
confirmed by a larger-scale study enrolling patients with recurrent
otomycosis unresponsive to standard treatments.
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